ECSP23070234A - Anti-cd30l antibodies and uses thereof - Google Patents

Anti-cd30l antibodies and uses thereof

Info

Publication number
ECSP23070234A
ECSP23070234A ECSENADI202370234A ECDI202370234A ECSP23070234A EC SP23070234 A ECSP23070234 A EC SP23070234A EC SENADI202370234 A ECSENADI202370234 A EC SENADI202370234A EC DI202370234 A ECDI202370234 A EC DI202370234A EC SP23070234 A ECSP23070234 A EC SP23070234A
Authority
EC
Ecuador
Prior art keywords
cd30l antibodies
cd30l
antibodies
ibd
disorders
Prior art date
Application number
ECSENADI202370234A
Other languages
English (en)
Inventor
Johan Fransson
Olivier Laurent
Burton Barnett
Mark Renshaw
Jessie-Farah Fecteau
Original Assignee
Dr Falk Pharma Gmbh
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh, Prometheus Biosciences Inc filed Critical Dr Falk Pharma Gmbh
Publication of ECSP23070234A publication Critical patent/ECSP23070234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se describen anticuerpos anti-CD30L y composiciones farmacéuticas para el tratamiento de enfermedades y trastornos autoinmunitarios tales como la enteropatía inflamatoria (IBD), incluida la enfermedad de Crohn (CD) y la colitis ulcerosa (UC).
ECSENADI202370234A 2021-02-17 2023-09-14 Anti-cd30l antibodies and uses thereof ECSP23070234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17

Publications (1)

Publication Number Publication Date
ECSP23070234A true ECSP23070234A (es) 2023-10-31

Family

ID=82931610

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202370234A ECSP23070234A (es) 2021-02-17 2023-09-14 Anti-cd30l antibodies and uses thereof

Country Status (18)

Country Link
US (2) US11866505B2 (es)
EP (1) EP4294840A1 (es)
JP (1) JP2024509746A (es)
KR (1) KR20230157356A (es)
CN (2) CN118047872A (es)
AR (1) AR124895A1 (es)
AU (1) AU2022224561A1 (es)
BR (1) BR112023016445A2 (es)
CA (1) CA3208060A1 (es)
CL (1) CL2023002393A1 (es)
CO (1) CO2023011962A2 (es)
CR (1) CR20230445A (es)
EC (1) ECSP23070234A (es)
IL (1) IL305146A (es)
MX (1) MX2023009621A (es)
PE (1) PE20231680A1 (es)
TW (1) TW202302637A (es)
WO (1) WO2022177963A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
WO2024026271A1 (en) * 2022-07-25 2024-02-01 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005018571A2 (en) 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
EP2769321B1 (en) * 2011-10-21 2016-06-01 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
IL307989A (en) * 2012-04-27 2023-12-01 Novo Nordisk As Human CD30 ligand antigen-binding proteins
US10358497B2 (en) * 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
WO2017127537A1 (en) 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
CN112368301A (zh) * 2018-04-30 2021-02-12 西达-赛奈医疗中心 用于选择和治疗炎性疾病患者的方法和***
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof

Also Published As

Publication number Publication date
CL2023002393A1 (es) 2024-03-22
PE20231680A1 (es) 2023-10-19
EP4294840A1 (en) 2023-12-27
MX2023009621A (es) 2023-10-31
KR20230157356A (ko) 2023-11-16
CN117255802A (zh) 2023-12-19
CA3208060A1 (en) 2022-08-25
US11866505B2 (en) 2024-01-09
TW202302637A (zh) 2023-01-16
CO2023011962A2 (es) 2023-09-29
US20230060624A1 (en) 2023-03-02
JP2024509746A (ja) 2024-03-05
CN118047872A (zh) 2024-05-17
IL305146A (en) 2023-10-01
AR124895A1 (es) 2023-05-17
AU2022224561A1 (en) 2023-09-28
AU2022224561A9 (en) 2023-10-05
US20240092923A1 (en) 2024-03-21
WO2022177963A1 (en) 2022-08-25
BR112023016445A2 (pt) 2023-12-12
CR20230445A (es) 2023-11-14

Similar Documents

Publication Publication Date Title
ECSP23070234A (es) Anti-cd30l antibodies and uses thereof
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
ECSP15038626A (es) A61k 30/395
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
PH12020551443A1 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
EA202091897A1 (ru) Неконденсированные производные тиофена и их применение
WO2019209995A3 (en) Optimized anti-tl1a antibodies
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
EA201890776A1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения
CO2020005200A2 (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios
MX2022004942A (es) Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
ECSP23070237A (es) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
BR112017002333A2 (pt) anticorpo ou um fragmento de ligação ao antígeno do anticorpo, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira transformada, e, método para produzir um anticorpo ou um fragmento de ligação ao antígeno do anticorpo.
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين
EA201790282A1 (ru) Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофил-эластазы
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
MX2020010425A (es) Composicion isotopicamente modificada y sus usos terapeuticos.
AR111845A1 (es) Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos